Chemomab receives FDA clearance to start Phase 2 trial of CM-101 in systemic sclerosis

Chemomab Therapeutics Ltd.

FDA cleared IND for Phase 2 ABATE trial of CM-101 in systemic sclerosis (SSc).
CM-101 is a first-in-class monoclonal antibody targeting CCL24; has Orphan Drug designation for SSc and PSC.
Trial to enroll 45 patients; primary endpoint safety; top-line data expected H2 2024.
CM-101 previously well-tolerated in early trials, reduced fibro-inflammatory biomarkers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.